FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to immunosuppressive polypeptides, which are trans-activator of transcription (Tat) derivatives, and can be used in medicine to treat an autoimmune disease, associated with an inflammation of a disease and/or a neurodegenerative disease. Immunosuppressive polypeptide comprises (i) a transcription factor (TF) domain, comprising a sequence of immunosuppressive human immunodeficiency virus (HIV), SIV Tat protein, hairless or artificial immunosuppressive sequence; (ii) a cysteine-rich domain from lentiviral Tat or a defensin molecule; and (iii) the C-terminal domain from the lentiviral protein Tat1.
EFFECT: invention enables to effectively inhibit an undesirable immune response in diseases characterised by aberrant immune responses.
14 cl, 17 dwg, 4 tbl, 8 ex
